Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The investigators design a phase II clinical study to explore the efficacy and safety of
toripalimab plus lenvatinib as a second-line treatment in patients with advanced biliary
tract cancers and to analyze potential biomarkers of therapeutic response.